EUCTR2008-008529-32-IT进行中（未招募）不适用
Evaluation of erdosteine effect on systemic inflamation biomarkers during COPD exacerbations - ERD/inflammation/COPD
.O.PNEUMOLOGIA- AZ. USL1 DI MASSA E CARRARA0 个研究点开始时间: 2009年1月5日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •hospitalized patiens with COPD exacerbation
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •severe systemic clinic complications
研究者
相似试验
进行中（未招募）
1 期
Effect of Erdosteine on inflammatory and oxidative biomarkers in sputum and exhaled breath in patients with COPD - Effect of Erdosteine ion lung inflammation and oxidation in COPDEUCTR2006-005534-20-GBImperial College London32
招募中
3 期
BronchiEctasis Trial Testing ERdosteine (BETTER)BronchiectasisACTRN12621000315819Queensland University of Technology194
Unknown
3 期
The Efficacy and Safety of Erdosteine in Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Disease (COPD)NCT01032304Edmond Pharma492
进行中（未招募）
1 期
The efficacy and safety of erdosteine in the long-term therapy of chronic obstructive pulmonary disease (COPD). A 12-month, randomised, double-blind, placebo-controlled, parallel group, multicenter study. - Study RESTOREChronic Obstructive Pulmonary DiseaseMedDRA version: 9.1 Level: LLT Classification code 10010952 Term: COPDEUCTR2008-008192-34-GBEdmond Pharma467
进行中（未招募）
1 期
The efficacy and safety of erdosteine in the long term therapy of Chronic Obstructive Pulmonary Disease (COPD). A 12-month, randomised, double blind, placebo-controlled, parallel group, multicenter, study - Study RESTOREChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 12.1Level: LLTClassification code 10010952Term: COPDEUCTR2008-008192-34-SKEDMOND PHARMA S.r.l.542